Findings from a new study published in the Journal of American College of Cardiology found that administration of the anti-viral drug Paxlovid can interact with several commonly prescribed cardiovascular drugs and be associated with an increased risk for blood clots and bleeding, which are termed clinically relevant drug-to-drug interactions (DDI).1 Manufactured by Pfizer, Paxlovid is […]
Albert Bourla is the CEO of Pfizer and just announced on Twitter that he has COVID. He said, “I would like to let you know that I tested positive for COVID-19. I am thankful to have received four doses of the Pfizer-BioNTech vaccine, and I am feeling well while experiencing mild symptoms. I am isolating […]
“I would like to let you know that I have tested positive for #COVID19. I am thankful to have received four doses of the Pfizer-BioNTech vaccine, and I am feeling well while experiencing very mild symptoms. I am isolating and have started a course of Paxlovid.” These were the words of Pfizer CEO Albert Bourla […]
On May 24, 2022, the U.S. Centers for Disease Control and Prevention (CDC) issued a health advisory to health care providers, public health departments and the general public regarding Pfizer’s antiviral drug Paxlovid, designed to treat symptoms of COVID-19. The advisory warns that some people who take Paxlovid may experience a recurrence of COVID symptoms […]
The U.S. Centers for Disease Control and Prevention (CDC) has admitted that COVID-19 patients may experience a rebound SARS-CoV-2 infection after taking Pfizer’s antiviral drug, Paxlovid. Evidence has shown that patients, including those who have gotten COVID shots and been boosted, may suffer a reoccurrence of COVID two to eight days after completing a five-day […]
Many scientists made a career fighting for better regulatory standards. Strangely, when it comes to the regulatory policy around COVID-19, they are dead quiet. First, consider that EUA ( emergency use authorization) is like accelerated approval. Both require lower levels of evidence, and are predicated on the fact that we’re dealing with a situation that […]
Merck and Pfizer have submitted Emergency Use Authorization (EUA) applications to the U.S. Food and Drug Administration (FDA) to authorize distribution of what would be the first antiviral drug specifically designed to treat COVID-19 disease.1 Merck/Ridgeback Biotherapeutics are seeking EUA approval for Molnupiravir (MK-4482/EIDD-2801), an investigational oral antiviral drug originally developed to treat influenza.2 Pfizer […]
